Please wait while the formulary information is being retrieved.
VISCO-3 (hyaluronate sodium)
- osteoarthritis of the knee
- Visco-3 Intra-articular Syringe
- Trivisc Intra-articular Syringe
- Triluron Intra-articular Syringe
- Synojoynt Intra-articular Syringe
- Supartz Fx Intra-articular Syringe
- Sodium Hyaluronate Intra-articular Syringe
- Hyalgan Intra-articular Syringe
- Genvisc 850 Intra-articular Syringe
- Euflexxa Intra-articular Syringe
- By Indication
10 mg/mL intra-articular syringe
- Inject 2 milliliters (20 mg) into the affected knee by intra-articular route every 7 days for 5 weeks
10 mg/mL intra-articular syringe
- Inject 2 milliliters (20 mg) into the affected knee by intra-articular route every 7 days for 5 weeks
10 mg/mL intra-articular syringe
- Inject 2 milliliters (20 mg) into the affected knee by intra-articular route every 7 days for 5 weeks
10 mg/mL intra-articular syringe
- Inject 2 milliliters (20 mg) into the affected knee by intra-articular route every 7 days for 5 weeks
10 mg/mL intra-articular syringe
- Inject 2 milliliters (20 mg) into the affected knee by intra-articular route every 7 days for 5 weeks
sodium hyaluronate 10 mg/mL intra-articular syringe
- Inject 2 milliliters (20 mg) into the affected knee by intra-articular route every 7 days for 5 weeks
sodium hyaluronate 10 mg/mL(mw 2.4-3.6 million)intra-articular syringe
- Inject 2 milliliters (20 mg) into the affected knee by intra-articular route every 7 days for 3 weeks
sodium hyaluronate 16.8 mg/2 mL intra-articular syringe
- Inject 2 milliliters (16.8 mg) into the affected knee(s) by intra-articular route every 7 days for 3 weeks
sodium hyaluronate 30 mg/2 mL intra-articular syringe
- Inject 2 milliliters (30 mg) by intra-articular route once weekly into the affected knee
10 mg/mL intra-articular syringe
- Inject 2 milliliters (20 mg) into the affected knee by intra-articular route every 7 days for 5 weeks
10 mg/mL intra-articular syringe
- Inject 2 milliliters (20 mg) into the affected knee by intra-articular route every 7 days for 5 weeks
10 mg/mL (mw 2.4-3.6 million) intra-articular syringe
- Inject 2 milliliters (20 mg) into the affected knee by intra-articular route every 7 days for 3 weeks
Default screening record
- Inject 2 milliliters (20 mg) into the affected knee by intra-articular route every 7 days for 5 weeks
- Inject 2 milliliters (20 mg) into left knee by intra-articular route every 7 days for 5 weeks
- Inject 2 milliliters (20 mg) into right knee by intra-articular routeevery 7 days for 5 weeks
- Inject 2 milliliters (20 mg) into the affected knee by intra-articular route every 7 days for 3 weeks
- Inject 2 milliliters (20 mg) into right knee by intra-articular routeevery 7 days for 3 weeks
- Inject 2 milliliters (20 mg) into left knee by intra-articular route every 7 days for 3 weeks
- Inject 2 milliliters (20 mg) into each knee by intra-articular route every 7 days for 3 weeks
- Inject 2 milliliters (20 mg) into each knee by intra-articular route every 7 days for 5 weeks
- Inject 2.5 milliliters (25 mg) into left knee by intra-articular route every 7 days for 3 weeks
- Inject 2.5 milliliters (25 mg) into right knee by intra-articular route every 7 days for 3 weeks
- Inject 2.5 milliliters (25 mg) into the affected knee by intra-articular route every 7 days for 3 weeks
- Inject 2.5 milliliters (25 mg) into the affected knee by intra-articular route every 7 days for 5 weeks
- Inject 2.5 milliliters (25 mg) into right knee by intra-articular route every 7 days for 5 weeks
- Inject 2.5 milliliters (25 mg) into left knee by intra-articular route every 7 days for 5 weeks
- Inject 2.5 milliliters (25 mg) into each knee by intra-articular route every 7 days for 3 weeks
- Inject 2.5 milliliters (25 mg) into each knee by intra-articular route every 7 days for 5 weeks
- None
Contraindicated
- None
Severe
Moderate
- None
- Infection of bone, joint, skin, or soft tissue of knee
Contraindicated
- None
Severe
Moderate
- None
VISCO-3 (hyaluronate sodium)
- osteoarthritis of the knee
- None
- Abdominal pain with cramps
- Anorexia
- Diarrhea
- Ecchymosis
- Gastrointestinal irritation
- Headache disorder
- Injection site sequelae
- Knee inflammation
- Nausea
- Pruritus of skin
- Vomiting
More Frequent
Severe
Less Severe
- Anaphylaxis
- Drug fever
- Skin rash
- Urticaria
- None
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- None
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
None
Hyaluronate
- Severity Level:
2
- Additional Notes: No fda rating; insufficient data available
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Hyaluronate Sodium
Insufficient human data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Osteoarthritis of the knee | |
| M17 | Osteoarthritis of knee |
| M17.0 | Bilateral primary osteoarthritis of knee |
| M17.1 | Unilateral primary osteoarthritis of knee |
| M17.10 | Unilateral primary osteoarthritis, unspecified knee |
| M17.11 | Unilateral primary osteoarthritis, right knee |
| M17.12 | Unilateral primary osteoarthritis, left knee |
| M17.2 | Bilateral post-traumatic osteoarthritis of knee |
| M17.3 | Unilateral post-traumatic osteoarthritis of knee |
| M17.30 | Unilateral post-traumatic osteoarthritis, unspecified knee |
| M17.31 | Unilateral post-traumatic osteoarthritis, right knee |
| M17.32 | Unilateral post-traumatic osteoarthritis, left knee |
| M17.4 | Other bilateral secondary osteoarthritis of knee |
| M17.5 | Other unilateral secondary osteoarthritis of knee |
| M17.9 | Osteoarthritis of knee, unspecified |
| 0-9 | A-Z |
|---|---|
| M17 | Osteoarthritis of knee |
| M17.0 | Bilateral primary osteoarthritis of knee |
| M17.1 | Unilateral primary osteoarthritis of knee |
| M17.10 | Unilateral primary osteoarthritis, unspecified knee |
| M17.11 | Unilateral primary osteoarthritis, right knee |
| M17.12 | Unilateral primary osteoarthritis, left knee |
| M17.2 | Bilateral post-traumatic osteoarthritis of knee |
| M17.3 | Unilateral post-traumatic osteoarthritis of knee |
| M17.30 | Unilateral post-traumatic osteoarthritis, unspecified knee |
| M17.31 | Unilateral post-traumatic osteoarthritis, right knee |
| M17.32 | Unilateral post-traumatic osteoarthritis, left knee |
| M17.4 | Other bilateral secondary osteoarthritis of knee |
| M17.5 | Other unilateral secondary osteoarthritis of knee |
| M17.9 | Osteoarthritis of knee, unspecified |
Formulary Reference Tool